|A Pin1/mutant p53 axis promotes aggressiveness in breast cancer|
JE Girardini, M Napoli, S Piazza, A Rustighi, C Marotta, E Radaelli, ...
Cancer cell 20 (1), 79-91, 2011
|Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)|
AM Thompson, LB Jordan, P Quinlan, E Anderson, A Skene, JA Dewar, ...
Breast cancer research 12 (6), 1-9, 2010
|CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations|
MA Province, MP Goetz, H Brauch, DA Flockhart, JM Hebert, R Whaley, ...
Clinical Pharmacology & Therapeutics 95 (2), 216-227, 2014
|Histological evaluation of AMPK signalling in primary breast cancer|
SM Hadad, L Baker, PR Quinlan, KE Robertson, SE Bray, G Thomson, ...
BMC cancer 9 (1), 1-9, 2009
|Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies|
E Amir, M Clemons, CA Purdie, N Miller, P Quinlan, W Geddie, ...
Cancer treatment reviews 38 (6), 708-714, 2012
|Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study|
CA Purdie, P Quinlan, LB Jordan, A Ashfield, S Ogston, JA Dewar, ...
British journal of cancer 110 (3), 565-572, 2014
|A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences|
AM Shaaban, GR Ball, RA Brannan, G Cserni, A Di Benedetto, J Dent, ...
Breast cancer research and treatment 133 (3), 949-958, 2012
|Therapeutic targeting of integrin αvβ6 in breast cancer|
KM Moore, GJ Thomas, SW Duffy, J Warwick, R Gabe, P Chou, IO Ellis, ...
JNCI: Journal of the National Cancer Institute 106 (8), 2014
|p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients|
JC Bourdon, MP Khoury, A Diot, L Baker, K Fernandes, M Aoubala, ...
Breast Cancer Research 13 (1), 1-10, 2011
|ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR|
C Thomas, G Rajapaksa, F Nikolos, R Hao, A Katchy, CW McCollum, ...
Breast cancer research 14 (6), 1-15, 2012
|Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy|
AM Thompson, A Johnson, P Quinlan, G Hillman, M Fontecha, SE Bray, ...
Breast cancer research and treatment 125 (1), 279-287, 2011
|Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome|
SI King, CA Purdie, SE Bray, PR Quinlan, LB Jordan, AM Thompson, ...
Breast cancer research 14 (2), 1-11, 2012
|High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer|
PG Roy, N Pratt, CA Purdie, L Baker, A Ashfield, P Quinlan, ...
International journal of cancer 127 (2), 355-360, 2010
|p53 mutation, deprivation and poor prognosis in primary breast cancer|
L Baker, PR Quinlan, N Patten, A Ashfield, LJ Birse-Stewart-Bell, ...
British journal of cancer 102 (4), 719-726, 2010
|Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome|
LA Henry, DA Johnson, D Sarrió, S Lee, PR Quinlan, T Crook, ...
Oncogene 30 (9), 1046-1058, 2011
|Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies.|
E Amir, M Clemons, OC Freedman, N Miller, RE Coleman, C Purdie, ...
Journal of Clinical Oncology 28 (15_suppl), 1007-1007, 2010
|The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer|
R Shah, P Smith, C Purdie, P Quinlan, L Baker, P Aman, AM Thompson, ...
British journal of cancer 100 (10), 1687-1696, 2009
|Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study|
CA Purdie, L Baker, A Ashfield, S Chatterjee, LB Jordan, P Quinlan, ...
British journal of cancer 103 (4), 475-481, 2010
|High frequency of complex TP53 mutations in CNS metastases from breast cancer|
CL Nigro, D Vivenza, M Monteverde, L Lattanzio, O Gojis, O Garrone, ...
British journal of cancer 106 (2), 397-404, 2012
|MAGE-A cancer/testis antigens inhibit MDM2 ubiquitylation function and promote increased levels of MDM4|
L Marcar, B Ihrig, J Hourihan, SE Bray, PR Quinlan, LB Jordan, ...
PloS one 10 (5), e0127713, 2015